Journal for ImmunoTherapy of Cancer View Homepage


Ontology type: schema:Periodical      Open Access: True


Journal Info

START YEAR

2013

PUBLISHER

BioMed Central

LANGUAGE

en

HOMEPAGE

http://jitc.biomedcentral.com

Recent publications latest 20 shown

  • 2019-12 Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
  • 2019-12 Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
  • 2019-12 Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors
  • 2019-12 Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
  • 2019-12 Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
  • 2019-12 HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
  • 2019-12 The motility regulator flhDC drives intracellular accumulation and tumor colonization of Salmonella
  • 2019-12 NKG2D signaling certifies effector CD8 T cells for memory formation
  • 2019-12 Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
  • 2019-12 Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
  • 2019-12 Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
  • 2019-12 Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence
  • 2019-12 A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
  • 2019-12 A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer
  • 2019-12 Two roads for oncolytic immunotherapy development
  • 2019-12 Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
  • 2019-12 TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways
  • 2019-12 Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
  • 2019-12 Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
  • 2019-12 A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B14000", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }
        ], 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "1.241", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "2.798", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2017", 
            "ratingValue": "8.374", 
            "type": "Rating"
          }
        ], 
        "description": "

    Journal for ImmunoTherapy of Cancer (JITC) is the premiere cancer immunotherapy journal at BMC, , and the official journal of the Society for Immunotherapy of Cancer (SITC). JITC welcomes basic, translational and clinical research and literature reviews on any aspect of tumor immunology and cancer immunotherapy. Topics of interest include tumor-host interactions, immune biomarkers, novel therapeutics, and immune-related toxicity.\u00a0 The journal\u2019s full collection, including its seminal guidelines and consensus statements, advances the rapidly evolving field of cancer immunotherapy through dissemination of rigorous peer-reviewed research.

    ", "editor": [ { "familyName": "Romero", "givenName": "Pedro", "type": "Person" } ], "id": "sg:journal.1049249", "inLanguage": [ "en" ], "isAccessibleForFree": true, "issn": [ "2051-1426" ], "license": "Fully Open Access", "name": "Journal for ImmunoTherapy of Cancer", "productId": [ { "name": "scopus_id", "type": "PropertyValue", "value": [ "21100466864" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "2051-1426/JOURNAL FOR IMMUNOTHERAPY OF CANCER" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "101620585" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "40425" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "2013254548" ] }, { "name": "dimensions_id", "type": "PropertyValue", "value": [ "49249" ] } ], "publisher": { "name": "BioMed Central", "type": "Organization" }, "publisherImprint": "BioMed Central", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1049249" ], "sdDataset": "journals", "sdDatePublished": "2019-03-18T11:05", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///home/ubuntu/piotr/scigraph_export/journals_20190313_sn_only.jsonl", "startYear": "2013", "type": "Periodical", "url": "http://jitc.biomedcentral.com" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1049249'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1049249'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1049249'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1049249'


     

    This table displays all metadata directly associated to this object as RDF triples.

    78 TRIPLES      21 PREDICATES      30 URIs      24 LITERALS      12 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1049249 schema:about sg:ontologies/product-market-codes/B14000
    2 sg:ontologies/product-market-codes/H33160
    3 schema:contentRating N0f08b900342c4e8ebba097b49458b6e4
    4 N1951bcec150f48ab80480589c97e0639
    5 Ncc21cb93982844869db7aac79e94c533
    6 schema:description <p><i>Journal for ImmunoTherapy of Cancer (JITC)</i> is the premiere cancer immunotherapy journal at BMC, , and the official journal of the Society for Immunotherapy of Cancer (SITC). JITC welcomes basic, translational and clinical research and literature reviews on any aspect of tumor immunology and cancer immunotherapy. Topics of interest include tumor-host interactions, immune biomarkers, novel therapeutics, and immune-related toxicity.  The journal’s full collection, including its seminal guidelines and consensus statements, advances the rapidly evolving field of cancer immunotherapy through dissemination of rigorous peer-reviewed research.</p>
    7 schema:editor N6bc678aa44d34ec59d577312fafa9d59
    8 schema:inLanguage en
    9 schema:isAccessibleForFree true
    10 schema:issn 2051-1426
    11 schema:license Fully Open Access
    12 schema:name Journal for ImmunoTherapy of Cancer
    13 schema:productId N051644a72dff47899dfa24dcc12eb826
    14 N3ed30752d56046baada008d0d44d4be2
    15 N4ad191e8c38a4af6b355e2331fc09caf
    16 N62a417037e2b498dbf40d817779a18e0
    17 N85a1aeccea56497f93bb7c234e5e53dd
    18 N87fd94a81c424cada68bf0f5337d9510
    19 schema:publisher Nbc0d06b6e5c24cc5a27ad8c45da03a44
    20 schema:publisherImprint BioMed Central
    21 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1049249
    22 schema:sdDatePublished 2019-03-18T11:05
    23 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    24 schema:sdPublisher N64451fa65dfa4d148545d188720865d9
    25 schema:startYear 2013
    26 schema:url http://jitc.biomedcentral.com
    27 sgo:license sg:explorer/license/
    28 sgo:sdDataset journals
    29 rdf:type schema:Periodical
    30 N051644a72dff47899dfa24dcc12eb826 schema:name springer_id
    31 schema:value 40425
    32 rdf:type schema:PropertyValue
    33 N0f08b900342c4e8ebba097b49458b6e4 schema:author N13edfafc05d14b62b48c900891a2588c
    34 schema:ratingValue 1.241
    35 rdf:type schema:Rating
    36 N13edfafc05d14b62b48c900891a2588c rdf:first snip
    37 rdf:rest rdf:nil
    38 N1951bcec150f48ab80480589c97e0639 schema:author N241e7872797f430ba1a4434daa98093d
    39 schema:dateCreated 2017
    40 schema:ratingValue 8.374
    41 rdf:type schema:Rating
    42 N1d0235389d25423c8b2f3d838d17e5bc schema:familyName Romero
    43 schema:givenName Pedro
    44 rdf:type schema:Person
    45 N241e7872797f430ba1a4434daa98093d rdf:first impact_factor_wos
    46 rdf:rest rdf:nil
    47 N3ed30752d56046baada008d0d44d4be2 schema:name wos_id
    48 schema:value 2051-1426/JOURNAL FOR IMMUNOTHERAPY OF CANCER
    49 rdf:type schema:PropertyValue
    50 N4ad191e8c38a4af6b355e2331fc09caf schema:name lccn_id
    51 schema:value 2013254548
    52 rdf:type schema:PropertyValue
    53 N62a417037e2b498dbf40d817779a18e0 schema:name dimensions_id
    54 schema:value 49249
    55 rdf:type schema:PropertyValue
    56 N64451fa65dfa4d148545d188720865d9 schema:name Springer Nature - SN SciGraph project
    57 rdf:type schema:Organization
    58 N6546b62745bb41b19280e72a4a2b873e rdf:first sjr
    59 rdf:rest rdf:nil
    60 N6bc678aa44d34ec59d577312fafa9d59 rdf:first N1d0235389d25423c8b2f3d838d17e5bc
    61 rdf:rest rdf:nil
    62 N85a1aeccea56497f93bb7c234e5e53dd schema:name scopus_id
    63 schema:value 21100466864
    64 rdf:type schema:PropertyValue
    65 N87fd94a81c424cada68bf0f5337d9510 schema:name nlm_unique_id
    66 schema:value 101620585
    67 rdf:type schema:PropertyValue
    68 Nbc0d06b6e5c24cc5a27ad8c45da03a44 schema:name BioMed Central
    69 rdf:type schema:Organization
    70 Ncc21cb93982844869db7aac79e94c533 schema:author N6546b62745bb41b19280e72a4a2b873e
    71 schema:ratingValue 2.798
    72 rdf:type schema:Rating
    73 sg:ontologies/product-market-codes/B14000 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    74 schema:name Immunology
    75 rdf:type schema:DefinedTerm
    76 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    77 schema:name Oncology
    78 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...